Home - Qynapse - The future of neuroimaging is here
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.
Overview
Qynapse is a company in the neuroimaging sector headquartered in Paris. The company develops neuroimaging software platforms to provide accurate and reliable predictors for central nervous system disorders, including Alzheimer's disease, multiple sclerosis, and Parkinson’s disease. Qynapse's flagship product, QyScore®, is an FDA-cleared and CE-marked platform that utilizes proprietary artificial intelligence to enhance the interpretation of MRI scans for physicians and researchers. Additionally, QyPredict® is a research-use-only platform that employs machine learning algorithms to improve understanding of disease trajectories in CNS disorders, potentially increasing the success rates of clinical trials. Qynapse collaborates with a team of scientific and clinical partners to advance the field of neuroimaging.
Details
- Category
- Medical Equipment Manufacturing
- Headquarters
- Paris
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Medical device, Neurology, Neuroimaging, Artificial Intelligence, Diagnosis, Prediction, Disease Trajectory, Monitoring, Drug Efficacy, Drug Safety, Personalized Medicine, Clinical Trials, Clinical Research, Central Nervous System, Azheimer's, Parkinson's, Dementia, Multiple Sclerosis, Stroke, and Psychiatry
- Locations
- 130 rue de Lourmel Paris, 75015, FR
50 Milk St Boston, Massachusetts 02119, US
Montreal, CA
Funding
Total rounds: 4
Last round: Seed, Jul 24, 2021
Last round amount: US$ 3.0M